FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Sponsor: Fate Therapeutics
Terminated
This study was terminated by the Sponsor.
A PHASE1 clinical study on Solid Tumor, Adult, this trial is terminated or withdrawn. The trial is conducted by Fate Therapeutics and has accumulated 6 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Nov 2021 — May 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fate Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .